Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Boehringer Ingelheim
Express Scripts
McKesson
Mallinckrodt

Last Updated: August 11, 2022

Investigational Drug Information for Henagliflozin


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Henagliflozin?

Henagliflozin is an investigational drug.

There have been 6 clinical trials for Henagliflozin. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2022.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Atrial Fibrillation, and [disabled in preview]. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Beijing Anzhen Hospital, and [disabled in preview].

There are three US patents protecting this investigational drug and thirty-five international patents.

Recent Clinical Trials for Henagliflozin
TitleSponsorPhase
Henagliflozin in Patients With Atrial FibrillationBeijing Anzhen HospitalPhase 3
Drug-drug Interaction Between Simvastatin and SHR3824Jiangsu HengRui Medicine Co., Ltd.Phase 1
The Drug-drug Interaction of SHR3824 and SP2086Jiangsu HengRui Medicine Co., Ltd.Phase 1

See all Henagliflozin clinical trials

Clinical Trial Summary for Henagliflozin

Top disease conditions for Henagliflozin
Top clinical trial sponsors for Henagliflozin

See all Henagliflozin clinical trials

US Patents for Henagliflozin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Henagliflozin See Plans and Pricing L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) See Plans and Pricing
Henagliflozin See Plans and Pricing Compounds as peptidic GLP1/glucagon/GIP receptor agonists SANOFI (Paris, FR) See Plans and Pricing
Henagliflozin See Plans and Pricing Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists SANOFI (Paris, FR) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Henagliflozin

Drugname Country Document Number Estimated Expiration Related US Patent
Henagliflozin Brazil BR112017005454 2034-09-30 See Plans and Pricing
Henagliflozin Canada CA2961819 2034-09-30 See Plans and Pricing
Henagliflozin China CN105992769 2034-09-30 See Plans and Pricing
Henagliflozin European Patent Office EP3202772 2034-09-30 See Plans and Pricing
Henagliflozin Spain ES2836099 2034-09-30 See Plans and Pricing
Henagliflozin Hungary HUE052588 2034-09-30 See Plans and Pricing
Henagliflozin Japan JP2017530107 2034-09-30 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Boehringer Ingelheim
Express Scripts
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.